There were 295 press releases posted in the last 24 hours and 256,994 in the last 365 days.

At a CAGR of 5.2%, Bipolar Disorder Treatment Market to Surpass US$ 10,925.5 Million globally by end of 2027, Says CMI

/EIN News/ -- SEATTLE, April 10, 2020 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global bipolar disorder treatment market is estimated to be valued at US$ 7,288.3 million in 2019 and is expected to exhibit a CAGR of 5.2% over the forecast period (2019-2027).

Key Trends and Analysis of the Global Bipolar Disorder Treatment Market:

Key trends in the market include increasing prevalence of mental disorders, increasing number of product launches, and increasing collaboration and acquisition activities by key market players.

Furthermore, according to the Organisation for Economic Co-operation and Development (OECD)/ European Union 2018 Report, around 84 million of European population has some mental health problems.

Request for Sample PDF copy @

The increasing product launches is expected to drive growth of the global bipolar disorder treatment market over the forecast period. For instance, in July 2017, Otsuka Pharmaceutical Co., Ltd. and H.Lundbeck A/S received the U.S. FDA approval for ABILIFY MAINTENA (aripiprazole), an extended-release injectable suspension, for the maintenance monotherapy treatment of bipolar I disorder (BP-I) in adults.

Furthermore, key players operating in the market are focused on increasing their manufacturing capabilities by launching new production lines, in order to expand their product offerings in the market. For instance, in May 2018, AstraZeneca entered into a license agreement with Luye Pharma Group, Ltd. for the sales and license of rights to Seroquel and Seroquel XR in the U.K., China, and other international markets, which include Brazil, Australia, Saudi Arabia, Mexico, South Korea, Thailand, Argentina, Malaysia, and South Africa.

Read Report Summary @

Key Market Takeaways:

  • The global bipolar disorder treatment market is expected to exhibit a CAGR of 5.2% over the forecast period, owing to increasing prevalence of mental illness and increasing number of product launches. According to The Argentine Department of Health, 2017, around 22% and 25% of population in Latin America and Caribbean, respectively, are expected to suffer from mental disorders throughout their lives.
  • North America is expected to hold the largest share in the global market, owing to presence of key players in the region such as Abbott, Hill-Rom Holdings, Inc., iRhythm Technologies, Inc., and AliveCor, and increased approval of new drugs for bipolar disorder treatment. For instance, in 2018, Sunovion Pharmaceuticals Inc. received the U.S. FDA approval for its supplemental new drug application (sNDA) that expands the use of Latuda (lurasidone HCI) to include the treatment of major depressive episode associated with bipolar I disorder (bipolar depression) in pediatric patients (aged 10-17 years).

Key players operating in the global bipolar disorder treatment market include

Takeda Pharmaceutical Company Limited, Pfizer, Inc., Allergan plc, Otsuka Holdings Co. Ltd., Johnson & Johnson, Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca Plc, Novartis International AG, AbbVie Inc., H. Lundbeck A/S, Minerva Neurosciences, Sumitomo Dainippon Pharma Co., Ltd., Intra-Cellular Therapies Inc., Gedeon Richter Plc., and Indivior PLC.

Buy this Report Now @

Market Segmentation:

  • Global Bipolar Disorder Treatment Market, By Drug Class:
    • Antipsychotics
    • Antidepressants
    • Mood Stabilizers
    • Anti-anxiety Drugs and Others
  • Global Bipolar Disorder Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Bipolar Disorder Treatment Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa

Did not find what you were looking for? Here are some similar topics:


Synthetic Opioids (CVIS) are opioid receptor agonists and act primarily on the brain and spinal cord and are used for pain relief. Most commonly prescribed synthetic opioids include, methadone, fentanyl and meperidine. Increasing prevalence of cancer is expected to boost growth of North America synthetic opioids market over the forecast period.

Read more @


Neuropathic pain is a condition which involves pain caused due to damage or diseases affecting the nervous system. These conditions may include diseases such as diabetes causing diabetic neuropathy, chemotherapy induced neuropathic pain, and trigeminal neuralgia. Diabetic neuropathy is the damage caused to the nerve due to diabetes which often leads to pain and numbness in feet or lower legs.

Read more @

Mr. Shah
Coherent Market Insights
1001 4th Ave. 
Seattle, WA 98154
Tel: +1-206-701-6702

Primary Logo